Antiviral research · 2006
Drug-resistant HIV-1 prevalence in patients newly diagnosed with HIV/AIDS in Japan.
Сравнительное исследованиеСтатьяПоддержка исследования: вне правительства СШАНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Gatanaga Hiroyuki, Ibe Shiro, Matsuda Masakazu, Yoshida Shigeru, Asagi Tsukasa, Kondo Makiko, Sadamasu Kenji, Tsukada Hiroki, Masakane Aki, Mori Haruyo, Takata Noboru, Minami Rumi, Tateyama Masao, Koike Takao, Itoh Toshihiro, Imai Mitsunobu, Nagashima Mami, Gejyo Fumitake, Ueda Mikio, Hamaguchi Motohiro, Kojima Yoko, Shirasaka Takuma, Kimura Akiro, Yamamoto Masahiro, Fujita Jiro, Oka Shinichi, Sugiura Wataru
Аннотация
The increasing prevalence of drug-resistant HIV transmission has become a critical epidemic in the world today. Studies in developed countries reported 8-27% of newly diagnosed HIV/AIDS patients are infected by drug-resistant strains. To determine the prevalence of drug-resistant HIV-1 among newly diagnosed cases in Japan, eight HIV/AIDS clinical centers, three public health laboratories and the National Institute of Infectious Diseases conducted a nationwide survey. Between January 2003 and December 2004, 575 newly diagnosed HIV/AIDS patients with both acute and chronic infections were enrolled in the study. Twenty-three cases, including three recently infected patients, were infected with HIV-1 having major drug-resistance mutations, including M41L, D67N, L100I, K103N, V106A, M184I, M184V, L210W, and revertant mutations at the 215 codon in reverse transcriptase and M46I in protease encoding regions. In this newly diagnosed population, we also clarified the prevalence of hepatitis virus coinfection, which was 8.8% for HBV and 4.3% for HCV. In conclusion, the drug-resistant transmission rate was 4.0% in Japan. Although this rate is significantly lower than that of other developed countries, this rate almost reaches the threshold at which baseline genotypic resistance testing would be cost-effective for all infected persons before initiating therapy.